The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Carl Norden - One of the best experts on this subject based on the ideXlab platform.
-
treating foot infections in diabetic patients a randomized multicenter open label trial of linezolid versus ampicillin sulbactam amoxicillin clavulanate
Clinical Infectious Diseases, 2004Co-Authors: Benjamin A Lipsky, Kamal M F Itani, Carl NordenAbstract:: Foot infections in diabetic patients are predominantly caused by gram-positive cocci, many of which are now antibiotic resistant. Because linezolid is active against these pathogens, we compared the efficacy and safety of intravenous and oral formulations with that of intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate given for 7-28 days in a randomized, open-label, multicenter study of all types of foot infection in diabetic patients (ratio of linezolid to comparator drug recipients, 2:1). Among 371 patients, the clinical cure rates associated with linezolid and the comparators were statistically equivalent overall (81% vs. 71%, respectively) but were significantly higher for linezolid-treated patients with infected foot ulcers (81% vs. 68%; P=.018) and for patients without osteomyelitis (87% vs. 72%; P=.003). Cure rates were comparable for inpatients and outpatients and for both oral and intravenous formulations. Drug-related adverse events were significantly more common in the linezolid group, but they were generally mild and reversible. Linezolid was at least as effective as Aminopenicillin/beta-lactamase inhibitors for treating foot infections in diabetic patients.
-
treating foot infections in diabetic patients a randomized multicenter open label trial of linezolid versus ampicillin sulbactam amoxicillin clavulanate
Clinical Infectious Diseases, 2004Co-Authors: Benjamin A Lipsky, Kamal M F Itani, Carl NordenAbstract:Foot infections in diabetic patients are predominantly caused by gram-positive cocci, many of which are now antibiotic resistant. Because linezolid is active against these pathogens, we compared the efficacy and safety of intravenous and oral formulations with that of intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate given for 7-28 days in a randomized, open-label, multicenter study of all types of foot infection in diabetic patients (ratio of linezolid to comparator drug recipients, 2:1). Among 371 patients, the clinical cure rates associated with linezolid and the comparators were statistically equivalent overall (81% vs. 71%, respectively) but were significantly higher for linezolid-treated patients with infected foot ulcers (81% vs. 68%; P = .018) and for patients without osteomyelitis (87% vs. 72%; P = .003). Cure rates were comparable for inpatients and outpatients and for both oral and intravenous formulations. Drug-related adverse events were significantly more common in the linezolid group, but they were generally mild and reversible. Linezolid was at least as effective as Aminopenicillin/β-lactamase inhibitors for treating foot infections in diabetic patients.
Benjamin A Lipsky - One of the best experts on this subject based on the ideXlab platform.
-
treating foot infections in diabetic patients a randomized multicenter open label trial of linezolid versus ampicillin sulbactam amoxicillin clavulanate
Clinical Infectious Diseases, 2004Co-Authors: Benjamin A Lipsky, Kamal M F Itani, Carl NordenAbstract:: Foot infections in diabetic patients are predominantly caused by gram-positive cocci, many of which are now antibiotic resistant. Because linezolid is active against these pathogens, we compared the efficacy and safety of intravenous and oral formulations with that of intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate given for 7-28 days in a randomized, open-label, multicenter study of all types of foot infection in diabetic patients (ratio of linezolid to comparator drug recipients, 2:1). Among 371 patients, the clinical cure rates associated with linezolid and the comparators were statistically equivalent overall (81% vs. 71%, respectively) but were significantly higher for linezolid-treated patients with infected foot ulcers (81% vs. 68%; P=.018) and for patients without osteomyelitis (87% vs. 72%; P=.003). Cure rates were comparable for inpatients and outpatients and for both oral and intravenous formulations. Drug-related adverse events were significantly more common in the linezolid group, but they were generally mild and reversible. Linezolid was at least as effective as Aminopenicillin/beta-lactamase inhibitors for treating foot infections in diabetic patients.
-
treating foot infections in diabetic patients a randomized multicenter open label trial of linezolid versus ampicillin sulbactam amoxicillin clavulanate
Clinical Infectious Diseases, 2004Co-Authors: Benjamin A Lipsky, Kamal M F Itani, Carl NordenAbstract:Foot infections in diabetic patients are predominantly caused by gram-positive cocci, many of which are now antibiotic resistant. Because linezolid is active against these pathogens, we compared the efficacy and safety of intravenous and oral formulations with that of intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate given for 7-28 days in a randomized, open-label, multicenter study of all types of foot infection in diabetic patients (ratio of linezolid to comparator drug recipients, 2:1). Among 371 patients, the clinical cure rates associated with linezolid and the comparators were statistically equivalent overall (81% vs. 71%, respectively) but were significantly higher for linezolid-treated patients with infected foot ulcers (81% vs. 68%; P = .018) and for patients without osteomyelitis (87% vs. 72%; P = .003). Cure rates were comparable for inpatients and outpatients and for both oral and intravenous formulations. Drug-related adverse events were significantly more common in the linezolid group, but they were generally mild and reversible. Linezolid was at least as effective as Aminopenicillin/β-lactamase inhibitors for treating foot infections in diabetic patients.
Jesus Oteo - One of the best experts on this subject based on the ideXlab platform.
-
novel mechanisms of resistance to β lactam antibiotics in haemophilus parainfluenzae β lactamase negative ampicillin resistance and inhibitor resistant tem β lactamases
Journal of Antimicrobial Chemotherapy, 2013Co-Authors: Silvia Garciacobos, Margarita Arroyo, Jose Campos, Maria Perezvazquez, Belen Aracil, Emilia Cercenado, Beatriz Orden, Noelia Lara, Jesus OteoAbstract:Results: Of the 20 non-susceptible isolates, 8 produced TEM b-lactamase (gBLPAR), 7 had mutations in the transpeptidase domain of the ftsI gene related to decreased susceptibility to b-lactams (gBLNAR) and 5 had both resistance mechanisms (gBLPACR). No resistance mechanisms were identified in the susceptible control group (gBLNAS). gBLNAR isolates had MIC90 values 4- to 16-fold higher than gBLNAS isolates for ampicillin, amoxicillin/clavulanic acid, cefuroxime, cefotaxime and cefixime, and the most common PBP3 mutation was Asn526Ser. The additional Ser385Thr substitution (III-like group) may confer decreased susceptibility to cefotaxime, cefixime and aztreonam, as in Haemophilus influenzae. In two b-lactamase-positive isolates without PBP3 mutations, the inhibitor-resistant TEM (IRT) b-lactamases TEM-34 and the novel TEM-182 were detected and carried by a TnA transposon of the Tn2 type; both isolates had an amoxicillin/clavulanic acid MIC of ≥ 8m g/L. The TnA transposons of two b-lactamase-positive isolates (TEM-1 and TEM-182) were inserted between the tfc20 and tfc21 genes, typically associated with integrative and conjugative elements in Haemophilus spp.; the TEM-34 IRT b-lactamase was harboured in a � 5.5 kb plasmid. Conclusions: Clinical isolates of H. parainfluenzae express a variety of Aminopenicillin resistance mechanisms, either alone or in combination, including PBP3 modifications, blaTEM-1 and IRT b-lactamase production.
Kamal M F Itani - One of the best experts on this subject based on the ideXlab platform.
-
treating foot infections in diabetic patients a randomized multicenter open label trial of linezolid versus ampicillin sulbactam amoxicillin clavulanate
Clinical Infectious Diseases, 2004Co-Authors: Benjamin A Lipsky, Kamal M F Itani, Carl NordenAbstract:: Foot infections in diabetic patients are predominantly caused by gram-positive cocci, many of which are now antibiotic resistant. Because linezolid is active against these pathogens, we compared the efficacy and safety of intravenous and oral formulations with that of intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate given for 7-28 days in a randomized, open-label, multicenter study of all types of foot infection in diabetic patients (ratio of linezolid to comparator drug recipients, 2:1). Among 371 patients, the clinical cure rates associated with linezolid and the comparators were statistically equivalent overall (81% vs. 71%, respectively) but were significantly higher for linezolid-treated patients with infected foot ulcers (81% vs. 68%; P=.018) and for patients without osteomyelitis (87% vs. 72%; P=.003). Cure rates were comparable for inpatients and outpatients and for both oral and intravenous formulations. Drug-related adverse events were significantly more common in the linezolid group, but they were generally mild and reversible. Linezolid was at least as effective as Aminopenicillin/beta-lactamase inhibitors for treating foot infections in diabetic patients.
-
treating foot infections in diabetic patients a randomized multicenter open label trial of linezolid versus ampicillin sulbactam amoxicillin clavulanate
Clinical Infectious Diseases, 2004Co-Authors: Benjamin A Lipsky, Kamal M F Itani, Carl NordenAbstract:Foot infections in diabetic patients are predominantly caused by gram-positive cocci, many of which are now antibiotic resistant. Because linezolid is active against these pathogens, we compared the efficacy and safety of intravenous and oral formulations with that of intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate given for 7-28 days in a randomized, open-label, multicenter study of all types of foot infection in diabetic patients (ratio of linezolid to comparator drug recipients, 2:1). Among 371 patients, the clinical cure rates associated with linezolid and the comparators were statistically equivalent overall (81% vs. 71%, respectively) but were significantly higher for linezolid-treated patients with infected foot ulcers (81% vs. 68%; P = .018) and for patients without osteomyelitis (87% vs. 72%; P = .003). Cure rates were comparable for inpatients and outpatients and for both oral and intravenous formulations. Drug-related adverse events were significantly more common in the linezolid group, but they were generally mild and reversible. Linezolid was at least as effective as Aminopenicillin/β-lactamase inhibitors for treating foot infections in diabetic patients.
Emilia Cercenado - One of the best experts on this subject based on the ideXlab platform.
-
novel mechanisms of resistance to β lactam antibiotics in haemophilus parainfluenzae β lactamase negative ampicillin resistance and inhibitor resistant tem β lactamases
Journal of Antimicrobial Chemotherapy, 2013Co-Authors: Silvia Garciacobos, Margarita Arroyo, Jose Campos, Maria Perezvazquez, Belen Aracil, Emilia Cercenado, Beatriz Orden, Noelia Lara, Jesus OteoAbstract:Results: Of the 20 non-susceptible isolates, 8 produced TEM b-lactamase (gBLPAR), 7 had mutations in the transpeptidase domain of the ftsI gene related to decreased susceptibility to b-lactams (gBLNAR) and 5 had both resistance mechanisms (gBLPACR). No resistance mechanisms were identified in the susceptible control group (gBLNAS). gBLNAR isolates had MIC90 values 4- to 16-fold higher than gBLNAS isolates for ampicillin, amoxicillin/clavulanic acid, cefuroxime, cefotaxime and cefixime, and the most common PBP3 mutation was Asn526Ser. The additional Ser385Thr substitution (III-like group) may confer decreased susceptibility to cefotaxime, cefixime and aztreonam, as in Haemophilus influenzae. In two b-lactamase-positive isolates without PBP3 mutations, the inhibitor-resistant TEM (IRT) b-lactamases TEM-34 and the novel TEM-182 were detected and carried by a TnA transposon of the Tn2 type; both isolates had an amoxicillin/clavulanic acid MIC of ≥ 8m g/L. The TnA transposons of two b-lactamase-positive isolates (TEM-1 and TEM-182) were inserted between the tfc20 and tfc21 genes, typically associated with integrative and conjugative elements in Haemophilus spp.; the TEM-34 IRT b-lactamase was harboured in a � 5.5 kb plasmid. Conclusions: Clinical isolates of H. parainfluenzae express a variety of Aminopenicillin resistance mechanisms, either alone or in combination, including PBP3 modifications, blaTEM-1 and IRT b-lactamase production.